Cooper Companies Stock Plummets 13% After Disappointing Q3 Earnings and Lowered Outlook

Investors in Cooper Companies (NYSE: COO) experienced a sharp jolt on August 28, 2025, as shares of the global medical device firm plunged by a significant 13%. The dramatic drop came on the heels of the company's fiscal third-quarter 2025 earnings report, which, despite showing growth, failed to meet Wall Street's elevated expectations and presented a more cautious outlook for the future.

The core of the market's disappointment stemmed from a marginal but impactful miss on both top-line revenue and bottom-line adjusted earnings per share (EPS).

Cooper Companies reported Q3 2025 revenue of $958.4 million, an 8% increase year-over-year. While robust, this figure fell just shy of the $962.3 million analysts had projected. Similarly, adjusted EPS came in at $3.57, a 7% rise from the previous year, but a penny below the anticipated $3.58.

However, the slightly missed historical numbers were compounded by revised guidance that truly spooked investors.

Cooper Companies lowered its outlook for both the upcoming fourth quarter and the full fiscal year 2025. For Q4, revenue guidance was trimmed to a range of $946 million to $966 million, a step down from the prior forecast of $968 million to $988 million. The full-year revenue projection also saw a reduction, now expected to be between $3.816 billion and $3.836 billion, down from the earlier range of $3.84 billion to $3.88 billion.

The adjustments weren't limited to revenue; full-year adjusted EPS guidance also experienced a slight haircut, moving from a previous range of $14.16 to $14.36 down to $14.12 to $14.24.

Management attributed part of this revised outlook to the strengthening U.S. dollar, which creates foreign currency headwinds for companies with significant international operations like Cooper Companies.

While the market reacted swiftly and negatively, it's crucial to put the dip into perspective.

Even after this substantial one-day fall, Cooper Companies stock remains in positive territory for the year, indicating a strong performance leading up to this point. The company continues to be a leader in the contact lens (CooperVision) and women's healthcare (CooperSurgical) markets, sectors with inherent long-term growth drivers.

For long-term investors, such sharp pullbacks, even if triggered by minor misses and guidance adjustments, often present an opportunity to re-evaluate or initiate positions in fundamentally strong companies.

While the immediate reaction was undeniably painful for shareholders, the underlying business quality and long-term trends in vision care and women's health may still make Cooper Companies an attractive prospect for those with a patient investment horizon.